Perioperative replacement therapy in haemophilia B: An appeal to “B” more precise

Haemophilia B is caused by a deficiency of coagulation factor IX (FIX) and characterized by bleeding in muscles and joints. In the perioperative setting, patients are treated with FIX replacement therapy to secure haemostasis. Targeting of specified FIX levels is challenging and requires frequent monitoring and adjustment of therapy.

[1]  F. Leebeek,et al.  A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patients , 2016, Haematologica.

[2]  Michael A Mont,et al.  Does Hemophilia Increase the Risk of Postoperative Blood Transfusion After Lower Extremity Total Joint Arthroplasty? , 2016, The Journal of arthroplasty.

[3]  F. Leebeek,et al.  Perioperative treatment of hemophilia A patients: blood group O patients are at risk of bleeding complications , 2016, Journal of thrombosis and haemostasis : JTH.

[4]  F. Baghaei,et al.  Nordic Hemophilia Guidelines , 2016 .

[5]  S. Björkman.  Comparative pharmacokinetics of factor VIII and recombinant factor IX: for which coagulation factors should half‐life change with age? , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[6]  J. Mahlangu,et al.  Guidelines for the management of hemophilia , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[7]  S. Björkman.  A commentary on the differences in pharmacokinetics between recombinant and plasma‐derived factor IX and their implications for dosing , 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

[8]  D Bergqvist,et al.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients , 2010, Journal of thrombosis and haemostasis : JTH.

[9]  A. Zakarija.  Factor IX replacement in surgery and prophylaxis , 2004, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[10]  A. Eisberg,et al.  Prophylaxis in factor IX deficiency product and patient variation , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

[11]  C. Leissinger,et al.  Continuous intravenous infusion of a plasma‐derived factor IX concentrate (Mononine®) in haemophilia B , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

[12]  K. Pasi,et al.  Use of recombinant factor IX in subjects with haemophilia B undergoing surgery , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

[13]  L. Sleeper,et al.  Surgery and Anesthesia in Sickle Cell Disease , 2002 .

[14]  A. Shapiro,et al.  Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis , 2001, Haemophilia : the official journal of the World Federation of Hemophilia.

[15]  Mannucci,et al.  Guidelines on replacement therapy for haemophilia and inherited coagulation disorders in Italy , 2000, Haemophilia : the official journal of the World Federation of Hemophilia.

[16]  Srivastava,et al.  Low‐dose intermittent factor replacement for post‐operative haemostasis in haemophilia , 1998, Haemophilia : the official journal of the World Federation of Hemophilia.

[17]  E. Berntorp,et al.  Multidose pharmacokinetics of factor IX: implications for dosing in prophylaxis , 1998, Haemophilia : the official journal of the World Federation of Hemophilia.

[18]  J. Lusher,et al.  Efficacy and safety of monoclonal antibody purified factor IX concentrate in haemophilia B patients undergoing surgical procedures , 1997, Haemophilia : the official journal of the World Federation of Hemophilia.

[19]  Scott T. Miller,et al.  Surgery and anesthesia in sickle cell disease. Cooperative Study of Sickle Cell Diseases. , 1995, Blood.